Cargando…

The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs

BACKGROUND: Following the emergence of the COVID-19 pandemic, the number of infected Brazilian people has increased dramatically since February 2020, with Brazil being amongst the countries with the highest number of cases and deaths. Brazilian vaccination began in January 2021, aimed at priority gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreira, Rafael da Silveira, Costa, Emilly Guaris, dos Santos, Lucas Fernando Rodrigues, Miranda, Luiz Henrique Lélis, de Oliveira, Raiany Rodrigues, Romão, Ricardo Fusano, Cozer, Rodolfo Ferreira, Guedes, Sarah Cavalcanti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110943/
https://www.ncbi.nlm.nih.gov/pubmed/35581560
http://dx.doi.org/10.1186/s12879-022-07449-5
_version_ 1784709216399785984
author Moreira, Rafael da Silveira
Costa, Emilly Guaris
dos Santos, Lucas Fernando Rodrigues
Miranda, Luiz Henrique Lélis
de Oliveira, Raiany Rodrigues
Romão, Ricardo Fusano
Cozer, Rodolfo Ferreira
Guedes, Sarah Cavalcanti
author_facet Moreira, Rafael da Silveira
Costa, Emilly Guaris
dos Santos, Lucas Fernando Rodrigues
Miranda, Luiz Henrique Lélis
de Oliveira, Raiany Rodrigues
Romão, Ricardo Fusano
Cozer, Rodolfo Ferreira
Guedes, Sarah Cavalcanti
author_sort Moreira, Rafael da Silveira
collection PubMed
description BACKGROUND: Following the emergence of the COVID-19 pandemic, the number of infected Brazilian people has increased dramatically since February 2020, with Brazil being amongst the countries with the highest number of cases and deaths. Brazilian vaccination began in January 2021, aimed at priority groups. This study analysed the spatial and temporal evolution of vaccination in Brazil between the 3rd and 21st epidemiological weeks (EW) of 2021. METHODS: Spatial and temporal analyses were performed comprising 19 EW. Cases were structured into priority groups—elderly population (EP); healthcare workers (HW); indigenous and quilombola populations (I/Q), dose, vaccine (CoronaVac or AstraZeneca), and place of vaccination. A sweep test was performed to identify vaccination rate clusters. Vaccination rates (VR) were calculated according to a spatial window for each Health Region, indicating clusters above/below expected VR. Based on the discrete Poisson probability model, spatial analysis was performed to detect high/low VR clusters, which were converted into Kernel maps. Points were generated from SaTScan analyses associated with Health Region centroids. Temporal analysis of VR was carried out to identify significant trends, and results were converted into temporal cluster graphs. P-value ≤ 0.05 was adopted. RESULTS: Southeast region concentrated most of the vaccines of EP and HW, followed by the Northeast. The latter region had the largest contingent of I/Q vaccinated. In all priority age groups and all regions, a higher percentage of complete CoronaVac vaccination schedules were observed compared with AstraZeneca. The temporal analysis identified high VR clusters of CoronaVac first and second dose in the early weeks, except for the EP; of AstraZeneca first dose, only for HW in the early weeks, and for EP and I/Q in the final weeks; of AstraZeneca second dose for all priority groups in the final weeks. I/Q populations had the lowest general VR. The spatial profile of VR indicated significant regional cluster differences between the priority groups. CONCLUSION: This study highlights the importance of establishing vaccination priority groups, considering the asymmetries that a pandemic can trigger, notably in vast geographic areas, to contemplate the main objective of vaccination: to prevent casualties.
format Online
Article
Text
id pubmed-9110943
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91109432022-05-17 The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Moreira, Rafael da Silveira Costa, Emilly Guaris dos Santos, Lucas Fernando Rodrigues Miranda, Luiz Henrique Lélis de Oliveira, Raiany Rodrigues Romão, Ricardo Fusano Cozer, Rodolfo Ferreira Guedes, Sarah Cavalcanti BMC Infect Dis Research BACKGROUND: Following the emergence of the COVID-19 pandemic, the number of infected Brazilian people has increased dramatically since February 2020, with Brazil being amongst the countries with the highest number of cases and deaths. Brazilian vaccination began in January 2021, aimed at priority groups. This study analysed the spatial and temporal evolution of vaccination in Brazil between the 3rd and 21st epidemiological weeks (EW) of 2021. METHODS: Spatial and temporal analyses were performed comprising 19 EW. Cases were structured into priority groups—elderly population (EP); healthcare workers (HW); indigenous and quilombola populations (I/Q), dose, vaccine (CoronaVac or AstraZeneca), and place of vaccination. A sweep test was performed to identify vaccination rate clusters. Vaccination rates (VR) were calculated according to a spatial window for each Health Region, indicating clusters above/below expected VR. Based on the discrete Poisson probability model, spatial analysis was performed to detect high/low VR clusters, which were converted into Kernel maps. Points were generated from SaTScan analyses associated with Health Region centroids. Temporal analysis of VR was carried out to identify significant trends, and results were converted into temporal cluster graphs. P-value ≤ 0.05 was adopted. RESULTS: Southeast region concentrated most of the vaccines of EP and HW, followed by the Northeast. The latter region had the largest contingent of I/Q vaccinated. In all priority age groups and all regions, a higher percentage of complete CoronaVac vaccination schedules were observed compared with AstraZeneca. The temporal analysis identified high VR clusters of CoronaVac first and second dose in the early weeks, except for the EP; of AstraZeneca first dose, only for HW in the early weeks, and for EP and I/Q in the final weeks; of AstraZeneca second dose for all priority groups in the final weeks. I/Q populations had the lowest general VR. The spatial profile of VR indicated significant regional cluster differences between the priority groups. CONCLUSION: This study highlights the importance of establishing vaccination priority groups, considering the asymmetries that a pandemic can trigger, notably in vast geographic areas, to contemplate the main objective of vaccination: to prevent casualties. BioMed Central 2022-05-17 /pmc/articles/PMC9110943/ /pubmed/35581560 http://dx.doi.org/10.1186/s12879-022-07449-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Moreira, Rafael da Silveira
Costa, Emilly Guaris
dos Santos, Lucas Fernando Rodrigues
Miranda, Luiz Henrique Lélis
de Oliveira, Raiany Rodrigues
Romão, Ricardo Fusano
Cozer, Rodolfo Ferreira
Guedes, Sarah Cavalcanti
The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs
title The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs
title_full The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs
title_fullStr The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs
title_full_unstemmed The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs
title_short The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs
title_sort assistance gaps in combating covid-19 in brazil: for whom, where and when vaccination occurs
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110943/
https://www.ncbi.nlm.nih.gov/pubmed/35581560
http://dx.doi.org/10.1186/s12879-022-07449-5
work_keys_str_mv AT moreirarafaeldasilveira theassistancegapsincombatingcovid19inbrazilforwhomwhereandwhenvaccinationoccurs
AT costaemillyguaris theassistancegapsincombatingcovid19inbrazilforwhomwhereandwhenvaccinationoccurs
AT dossantoslucasfernandorodrigues theassistancegapsincombatingcovid19inbrazilforwhomwhereandwhenvaccinationoccurs
AT mirandaluizhenriquelelis theassistancegapsincombatingcovid19inbrazilforwhomwhereandwhenvaccinationoccurs
AT deoliveiraraianyrodrigues theassistancegapsincombatingcovid19inbrazilforwhomwhereandwhenvaccinationoccurs
AT romaoricardofusano theassistancegapsincombatingcovid19inbrazilforwhomwhereandwhenvaccinationoccurs
AT cozerrodolfoferreira theassistancegapsincombatingcovid19inbrazilforwhomwhereandwhenvaccinationoccurs
AT guedessarahcavalcanti theassistancegapsincombatingcovid19inbrazilforwhomwhereandwhenvaccinationoccurs
AT moreirarafaeldasilveira assistancegapsincombatingcovid19inbrazilforwhomwhereandwhenvaccinationoccurs
AT costaemillyguaris assistancegapsincombatingcovid19inbrazilforwhomwhereandwhenvaccinationoccurs
AT dossantoslucasfernandorodrigues assistancegapsincombatingcovid19inbrazilforwhomwhereandwhenvaccinationoccurs
AT mirandaluizhenriquelelis assistancegapsincombatingcovid19inbrazilforwhomwhereandwhenvaccinationoccurs
AT deoliveiraraianyrodrigues assistancegapsincombatingcovid19inbrazilforwhomwhereandwhenvaccinationoccurs
AT romaoricardofusano assistancegapsincombatingcovid19inbrazilforwhomwhereandwhenvaccinationoccurs
AT cozerrodolfoferreira assistancegapsincombatingcovid19inbrazilforwhomwhereandwhenvaccinationoccurs
AT guedessarahcavalcanti assistancegapsincombatingcovid19inbrazilforwhomwhereandwhenvaccinationoccurs